Dare Bioscience (DARE) Non-Current Assets (2013 - 2026)
Dare Bioscience's (DARE) quarterly Non-Current Assets came in at $5.4 million in Q4 2025, up 48.11% YoY from $3.7 million in Q4 2024, and down 5.81% on a QoQ basis from $5.7 million in Q3 2025.
Dare Bioscience (DARE) Non-Current Assets (2013 - 2026) Analysis & Trends
Dare Bioscience (DARE) has 13 years of Non-Current Assets data on file, last reported at $5.4 million in Q4 2025.
- Quarterly Non-Current Assets rose 48.11% year-over-year to $5.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $24.3 million (up 93.5% YoY) and the FY2025 annual result came in at $5.4 million, up 48.11% from the prior year.
- Non-Current Assets eased to $5.4 million in Q4 2025, from $5.7 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $6.8 million in Q1 2025 to a low of $511161.0 in Q4 2021.
- A 5-year average of $2.6 million and a median of $2.0 million in 2022 frame the typical range for Non-Current Assets.
- The widest YoY moves for Non-Current Assets: up 374.67% in 2023, down 37.58% in 2023.
- Tracing DARE's Non-Current Assets over 5 years: stood at $511161.0 in 2021, then surged by 54.09% to $787630.0 in 2022, then surged by 374.67% to $3.7 million in 2023, then dropped by 2.28% to $3.7 million in 2024, then surged by 48.11% to $5.4 million in 2025.
- The last three Non-Current Assets figures came in at $5.4 million (Q4 2025), $5.7 million (Q3 2025), and $6.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.18 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.37 Bn | 59.19 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.75 Bn | 9.35 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.24 Bn | 26.08 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.03 Bn | 26.20 Bn | - | 18.06 Bn |
| 10 | Dare Bioscience | 12.21 Mn | -406,442.64 | -132,343.00 | 5.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.68 Mn |
| Dec 31, 2025 | 5.41 Mn |
| Sep 30, 2025 | 5.74 Mn |
| Jun 30, 2025 | 6.38 Mn |
| Mar 31, 2025 | 6.80 Mn |
| Dec 31, 2024 | 3.65 Mn |
| Sep 30, 2024 | 3.11 Mn |
| Jun 30, 2024 | 2.78 Mn |
| Mar 31, 2024 | 3.03 Mn |
| Dec 31, 2023 | 3.74 Mn |
| Sep 30, 2023 | 2.62 Mn |
| Jun 30, 2023 | 966,665.00 |
| Mar 31, 2023 | 854,727.00 |
| Dec 31, 2022 | 787,630.00 |
| Sep 30, 2022 | 809,347.00 |
| Jun 30, 2022 | 1.28 Mn |
| Mar 31, 2022 | 1.37 Mn |
| Dec 31, 2021 | 511,161.00 |
| Sep 30, 2021 | 568,322.00 |
| Jun 30, 2021 | 763,190.00 |